Nivalis Therapeutics

Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of product candidates for patients with cystic fibrosis (CF). CF is a life-shortening genetic disease. Its lead product candidate is N91115, a small molecule that is in Phase II clinical trial, which addresses a defect in cystic fibrosis transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. The company was formerly known as N30 Pharmaceuticals, Inc. and changed its name to Nivalis Therapeutics, Inc. in February 2015. Nivalis Therapeutics, Inc. was founded in 2007 and is headquartered in Boulder, Colorado.
Type
Public
HQ
Boulder, US
Founded
2007
Size (employees)
29 (est)
Nivalis Therapeutics was founded in 2007 and is headquartered in Boulder, US

Nivalis Therapeutics Office Locations

Nivalis Therapeutics has an office in Boulder
Boulder, US (HQ)
200 3122 Sterling Dr

Nivalis Therapeutics Data and Metrics

Nivalis Therapeutics Financial Metrics

USD

Net income (Q1, 2017)

(8.9 m)

Market capitalization (24-Jul-2017)

9.4 m

Cash (31-Mar-2017)

12.9 m
Nivalis Therapeutics's current market capitalization is $9.4 m.
USDFY, 2015FY, 2016

Net Income

(22.8 m)(31.5 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(10.2 m)(16.3 m)(7.8 m)(16.3 m)(23.8 m)(8.9 m)
USDFY, 2015FY, 2016

Cash

25 m24.2 m

Accounts Receivable

476 m

Inventories

432 k628 k

Current Assets

87.7 m61.7 m

Total Assets

87.9 m61.9 m

Accounts Payable

994 k1.9 m

Current Liabilities

4.4 m6.5 m

Additional Paid-in Capital

232.3 m235.7 m

Retained Earnings

(148.8 m)(180.3 m)

Total Equity

83.5 m55.4 m

Financial Leverage

1.1 x1.1 x
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

100.5 m57.6 m16 m15.4 m16.2 m12.9 m

Current Assets

101.1 m93.6 m80.7 m74.2 m67 m52.9 m

Total Assets

101.2 m93.8 m80.9 m74.6 m67.3 m53 m

Accounts Payable

3.4 m1.6 m1.2 m2.1 m1 m1.3 m

Current Liabilities

6.1 m4.5 m4.6 m5.9 m5.2 m3.8 m

Additional Paid-in Capital

231.3 m231.6 m233 m233.8 m234.7 m238.4 m

Retained Earnings

(136.2 m)(142.3 m)(156.7 m)(165.2 m)(172.6 m)(189.2 m)

Total Equity

95.1 m89.4 m76.4 m68.7 m62.1 m49.2 m

Financial Leverage

1.1 x1 x1.1 x1.1 x1.1 x1.1 x
USDFY, 2015FY, 2016

Net Income

(22.8 m)(31.5 m)

Accounts Payable

65 k927 k

Cash From Operating Activities

(19.2 m)(26.3 m)

Purchases of PP&E

(188 k)(106 k)

Cash From Investing Activities

(62.4 m)25.3 m

Cash From Financing Activities

78.8 m166 k

Interest Paid

165 k165 k
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(10.2 m)(16.3 m)(7.8 m)(16.3 m)(23.8 m)(8.9 m)

Depreciation and Amortization

31 k47 k30 k66 k104 k57 k

Accounts Payable

419 k623 k202 k1.1 m18 k(643 k)

Cash From Operating Activities

(8.1 m)(13.8 m)(7 m)(13.6 m)(21.1 m)(8.4 m)

Purchases of PP&E

(87 k)(142 k)(31 k)(74 k)(90 k)(31 k)

Cash From Investing Activities

(87 k)(35.2 m)(2 m)3.9 m12.2 m(2.8 m)

Cash From Financing Activities

80.9 m78.8 m92 k103 k

Interest Paid

124 k165 k
Y, 2017

Financial Leverage

1.1 x

Nivalis Therapeutics Operating Metrics

Nivalis Therapeutics's Patent Applications was reported to be 42 in FY, 2016
FY, 2016

Patents Issued

245

Patent Applications

42

Patents Licensed

12

Nivalis Therapeutics Market Value History

Nivalis Therapeutics Online and Social Media Presence

Nivalis Therapeutics Company Life and Culture

You may also be interested in